Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News TCT 2021

DCBs in Coronaries? Some Good News, but More Work Needed

L.A. McKeown

November 06, 2021

Presentation TCT 2021

One-year Outcomes of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions

Presenter: Bruno Scheller

November 06, 2021

Presentation TCT 2021

A Randomized Trial of Sirolimus-coated Versus Paclitaxel-coated Balloons in De Novo Coronary Lesions

Presenter: Wan Azman Wan Ahmad

November 06, 2021

Presentation TCT 2021

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

Presenter: Runlin Gao

November 05, 2021

Presentation TCT 2021

The MAGICAL trial – Insights from the upcoming US IDE DCB study

Presenter: Martin Leon

November 05, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

Advertisement

DCBs in Coronaries? Some Good News, but More Work Needed

One-year Outcomes of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions

A Randomized Trial of Sirolimus-coated Versus Paclitaxel-coated Balloons in De Novo Coronary Lesions

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

The MAGICAL trial – Insights from the upcoming US IDE DCB study

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Good Long-term Results With FANTOM BVS, but More Data Needed

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content